Malaria

Professor Pedro L. Alonso

Director, Barcelona Institute for Global Health (ISGlobal), Spain

Dr Pedro Alonso is also Director of the Barcelona Centre for International Health Research (CRESIB); Head of the International Health and Tropical Medicine Unit of the Hospital Clinic of Barcelona; Professor at the University of Barcelona; and President of the Governing Board of the Manhiça Foundation / Manhiça Health Research Centre (CISM) in Mozambique.

Dr. Pedro Alonso started his career in international health 25 years ago as a young physician working in West Africa. Since then, his work has focused on the key determinants of morbidity and mortality in the two most vulnerable population groups in Africa: young children and pregnant women. He is increasingly active in building and strengthening human and institutional capacity in developing countries and Europe and in campaigning for support for other global health initiatives.

Some of his most relevant work has been carried out in the field of malaria and has led to the development and testing of new tools for the prevention and treatment of Plasmodium falciparum. He conducted the first trials to show the impact of insecticide-treated nets in the reduction of all-cause mortality (Lancet 1991) as well as phase 2b trials of the first malaria vaccine candidate (RTS,S) in Africa (Lancet 1994) and the first proof-of-concept trials of RTS,S in African children and infants (Lancet 2004 and 2007). He is also lead author on papers showing the safety and efficacy of iron supplementation in young infants in malaria-endemic areas (Lancet 1997) and presenting the first proof of concept of intermittent preventive treatment in infants as a potential malaria control tool (Lancet 2001). He has published more than 300 papers in international peer-reviewed journals.

Between 2005 and 2007, together with Professor Fred Binka, he led the steering committee that designed and implemented the European Union EDCTP (European and Developing Countries Clinical Trials Partnership) initiative. He has served on several national and international committees. Currently, he is a board member of the Medicines for Malaria Venture, Co-Chair of the Steering Committee of the Decade of Vaccines Collaboration an initiative promoted by WHO, UNICEF, the National Institute of Allergy and Infectious Diseases and the Bill & Melinda Gates Foundation, and Chair of the Steering Committee of the Malaria Eradication Scientific Alliance, MESA. He is also a member of the WHO Malaria Policy Advisory Committee.

Share